ライフサイエンスコーパス: SLN

1 SLN and ALND groups and radiation fields were compared w

2 SLN binding to SERCA uncouples Ca(2+) transport from ATP

3 SLN biopsy is recommended for patients with intermediate

4 SLN biopsy may be considered for thin melanomas that are

5 SLN biopsy may be recommended for patients with thick me

6 SLN counts were performed in vivo and confirmed ex vivo.

7 SLN has also been implicated in skeletal muscle thermoge

8 SLN physically interacts with SERCA and differentially r

9 SLN surgery is increasingly used for nodal staging after

10 SLN used for co-crystallization with SERCA1a is also pal

11 SLN(s) are more reliably identified with ICG dose >=1 mg

12 SLNs formulated with GS were fully digested, similarly t

13 SLNs-loaded MNs exhibited sufficient mechanical and inse

14 The median overall detection (>/=1 SLN in a patient) was 98.6% for SPECT/CT (range, 92.2%-1

15 he reported median bilateral detection (>/=1 SLN in each hemipelvis) was 69.0% for SPECT/CT (range, 6

16 hoscintigraphy was able to depict at least 1 SLN in 339 of 352 breast lesions (96.3%), and the intrao

17 At least 1 SLN was identified in 639 patients (92.7%: 95% CI: 90.5%

18 We show that: 1) SLN values constrain models of cortical hierarchy, revea

19 In 75 cases, 136 SLNs were eligible for analysis, of which 13 (9.6%) cont

20 In these 80 surgical procedures, 147 SLNs were excised.

21 7%) patients with cN1 disease and at least 2 SLNs resected, clip location was confirmed in 141 cases.

22 des removed compared with a median of only 2 SLNs removed with SLND alone (P < 0.001).

23 g previously unsuspected areal relations; 2) SLN reflects the operation of a combinatorial distance r

24 indications for ALND were metastases in >/=3 SLNs or gross extracapsular extension.

25 The sialylated HMOs 3'SL and 3'SLN were associated with fasting glucose; LDFT was assoc

26 3'SL and 3'SLN, but not 2'FL or LDFT, at 15 wk were positively asso

27 llactose (3'SL), and 3'-sialyllactosamine (3'SLN)] were measured.

28 In 484 SLN-only patients with known RT fields (103 prone, 280 s

29 Four of the 5 SLNs exhibited increased SUVs of 12.4-139.0 obtained fro

30 5FU-SLN(4) was highly cytotoxic against HCT-116 cells and si

31 Among the all the formulations, 5FU-SLN(4) was the most effective with particle size of was

32 The IC(50) value of 5FU-SLN(4) (7.4 +/- 0.02 uM) was 2.3 fold low compared with

33 the effectiveness and cellular uptake of 5FU-SLN(4) in HCT-116 cancer cells.

34 plasma concentration-time curve (AUC) of 5FU-SLN(4) was 3.6 fold high compared with 5-FU.

35 For tumor efficacy studies, 5FU-SLN(4) significantly inhibited tumor growth in compariso

36 An alignment of 67 SLN sequences from the protein databases shows that 19 o

37 (2+)-ATPase assays showed that sAnk1 ablated SLN's inhibition of SERCA1 activity.

38 SLN caused the resulting chimera to acquire SLN-like function.

39 in muscle succinate dehydrogenase activity, SLN expression, mitochondrial content, and neovasculariz

40 view the evidence that regression may affect SLN status.

41 ith a single tumor-positive lymph node after SLN biopsy underwent CLND and were randomly assigned to

42 Five-year event-free survival after SLN alone was 93% with no isolated axillary recurrences.

43 in locoregional recurrence or survival after SLN biopsy alone or ALND.

44 d the novel interaction between SERCA and an SLN monomer.

45 The clipped node was not retrieved as an SLN in 23% (31 of 134) of patients, including six with n

46 tivity, which established a lymph node as an SLN.

47 which allowed the direct visualization of an SLN pentamer.

48 .010) compared with patients who received an SLN biopsy.

49 Patients underwent an SLN procedure with preoperative (99m)Tc-nanocolloid SPEC

50 tle/abstract and considered eligible when an SLN procedure was performed using both imaging modalitie

51 f isosulfan blue dye to radioisotope when an SLN was identified on a preoperative lymphoscintigram.

52 Patients in whom an SLN biopsy was not performed had significantly reduced M

53 by an additional density consistent with an SLN monomer.

54 On univariable analysis, SLN detection rates did not differ by age, clinical T or

55 FNR of 9.8% with the combination of AUS and SLN surgery would be acceptable for the adoption of SLN

56 istologic regression of primary melanoma and SLN status.

57 utagenesis and generated chimeras of PLB and SLN.

58 Although the sequences of PLN and SLN are practically invariant among mammals, they vary i

59 In contrast to PLN and SLN, which are expressed in cardiac and slow skeletal mu

60 Our results indicated that sAnk1 and SLN can associate in the sarcoplasmic reticulum membrane

61 association with pathologic nodal status and SLN FNR.

62 These studies suggest that UCP1 and SLN are required to maintain optimal thermogenesis and t

63 e cold adaptation by employing UCP1(-/-) and SLN(-/-) mice.

64 ety of Surgical Oncology recommendations are SLN positive.

65 rformed with other axillary surgery, such as SLN dissection.

66 operative (99m)Tc-nanocolloid SPECT/CT-based SLN mapping.

67 suggest that domains can be switched between SLN and PLB without losing the ability to regulate SERCA

68 In this study, we used both SLN knockout (Sln(-/-)) and skeletal muscle-specific SLN

69 subareolarly for localization of the breast SLN and isosulfan blue dye (5 mL) is injected in the ips

70 um Ca(2+) cycling and that its regulation by SLN can be the basis for muscle NST.

71 In 80 cases, SLN biopsy resulted in a positive lymph node.

72 ed node should be considered when conducting SLN surgery in this setting.

73 However, HPO-containing SLNs presented slower lipolysis kinetics during the inte

74 ich the final pathology of the corresponding SLNs was negative for tumor.

75 ets of the SPECT and MR images were created, SLNs could be identified on the MR image with accurate c

76 sonic imaging system to noninvasively detect SLNs based on the accumulation of methylene blue dye.

77 n the mean number of histologically detected SLNs had to be greater than -0.27 (10% noninferiority ma

78 wed a mean number of histologically detected SLNs of 2.21 with LSG and 2.26 without LSG (difference 0

79 s the mean number of histologically detected SLNs per patient.

80 s into a therapeutic strategy, we knock down SLN expression in 1-month old mdx:utr (-/-) mice via ade

81 compared to 0.60 g/100 g in the spray-dried SLNs.

82 ease with removal of the clipped node during SLN surgery reduces the FNR of SLN surgery after neoadju

83 nguinal lymph nodes pathologically examined (SLN + MILND) was 12.0 (interquartile range 8.0, 14.0).

84 ive lymphoscintigraphic detection or excised SLNs was higher with superficial than deep injections.

85 FireFly camera system to detect fluorescent SLNs after administration of a dual-labeled molecular im

86 the trunk), the use of indocyanine green for SLN detection is severely limited compared with SLNE usi

87 impact of AUS results to select patients for SLN surgery to reduce the FNR was assessed.

88 Local protocols for SLN detection within 9 participant centers were not chan

89 en together, establish an important role for SLN in muscle metabolism and energy expenditure.

90 roup of breast cancer patients scheduled for SLN biopsy.

91 normal nodes and guide patient selection for SLN surgery.

92 staging after NAC and optimal technique for SLN identification is important.

93 polymeric hydrogel which was casted to form SLNs-loaded MNs.

94 swapping PLB N and C termini with those from SLN caused the resulting chimera to acquire SLN-like fun

95 Drug release was sustained over 48h from SLNs, compared to pure drugs.

96 ors expression were markedly reduced in 5-FU-SLN(4) treated mice compared with 5FU and liver and kidn

97 In total, 66 patients underwent NIR-guided SLN mapping and lymphadenectomy after peritumoral ICG in

98 NIR-guided SLN mapping may improve staging and outcomes through ide

99 e I clinical trials investigating NIR-guided SLN mapping utilizing ICG in patients with surgically re

100 ligible, 12 underwent ALND only, and 689 had SLN surgery attempted.

101 ients met Z0011 eligibility criteria and had SLN metastases.

102 Patients eligible for Z0011 had SLN biopsy alone.

103 ality studies had a lower likelihood to have SLN positivity (OR, 0.48; 95% CI, 0.32-0.72) compared wi

104 th regression had a lower likelihood to have SLN positivity (OR, 0.56; 95% CI, 0.41-0.77) than patien

105 Lymphoscintigraphy showed higher SLN detection in patients with a normal weight (body mas

106 However, the detailed mechanism of how SLN regulates muscle metabolism remains unclear.

107 Currently, however, SLN mapping requires LN biopsy for pathologic evaluation

108 Despite this, HPO-SLNs showed higher beta-carotene bioaccessibility, which

109 echnique was the only factor found to impact SLN identification; with use of blue dye alone increasin

110 These results confirm that immediate CLND in SLN-positive patients is not superior to observation in

111 to the histologic result of each individual SLN.

112 ssion modeling assessing factors influencing SLN identification was performed.

113 east lesions (96.3%), and the intraoperative SLN detection rate reached 97.2%.

114 sequent verification of fluorescence-labeled SLNs during robotic-assisted surgery.

115 carriers, including nanoemulsion, liposomes, SLN, NLC etc.

116 therefore, the exploration of sentinel LNs (SLNs) is highly important.

117 nal tail causes the chimeric protein to lose SLN-like function.

118 Detection of a technetium Tc 99m-marked SLN before surgery was possible in all cases.

119 By this mechanism, SLN promotes the futile cycling of SERCA, contributing t

120 Women with one to two metastatic SLNs planning to undergo breast-conserving surgery with

121 Women with one to two metastatic SLNs who are planning to undergo breast-conserving surge

122 fused SPECT/MR images and scored morphologic SLN parameters on a standardized case report form.

123 After NAC, SLN surgery and axillary lymph node dissection (ALND) we

124 he second approach solid lipid nanoparticle (SLN) dispersions of DHA, were first produced by high-pre

125 g delivery system, solid lipid nanoparticle (SLN), capable of delivering high payload of 5-FU to trea

126 l applications of solid lipid nanoparticles (SLN) as oral delivery vehicles.

127 al arrangement of solid lipid nanoparticles (SLN).

128 e approach, using solid lipid nanoparticles (SLNs) and dissolving microneedles (MNs) to deliver antif

129 Solid lipid nanoparticles (SLNs) are emulsion-based carriers of lipophilic bioactiv

130 ed NPs (Liposome, solid-lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs)), etc.

131 DRFS compared with patients with a negative SLN, unless an immediate completion lymph node dissectio

132 100% in those with a histologically negative SLN identified (n = 25) compared to 73.6% (P = 0.02) and

133 Among patients with tumor-negative SLN by conventional pathology but with melanoma detected

134 In Protocol B, patients with tumor-negative SLN by standard histopathology and immunohistochemistry

135 34) of patients, including six with negative SLNs but metastasis in the clipped node.

136 percentage of supragranular labeled neurons [SLN]).

137 To date, N0 status when established via NIR SLN mapping seems to be associated with decreased recurr

138 th melanoma who undergo sentinel lymph node (SLN) biopsy based on American Society of Clinical Oncolo

139 radiopharmaceutical for sentinel lymph node (SLN) biopsy in breast cancer.

140 ogy (SSO) guideline for sentinel lymph node (SLN) biopsy in melanoma.

141 regarding the need for sentinel lymph node (SLN) biopsy when regression is present within the primar

142 with melanoma staged by sentinel lymph node (SLN) biopsy.

143 n overall and bilateral sentinel lymph node (SLN) detection in cervical cancer patients.

144 atients with a positive sentinel lymph node (SLN) had significantly reduced melanoma-specific surviva

145 accurate targeting for sentinel lymph node (SLN) mapping during robotic-assisted surgery has yet to

146 Women without sentinel lymph node (SLN) metastases should not receive axillary lymph node d

147 onclusion Women without sentinel lymph node (SLN) metastases should not receive axillary lymph node d

148 e factors predictive of sentinel lymph node (SLN) metastasis in thin melanoma.

149 negative rate (FNR) for sentinel lymph node (SLN) surgery after neoadjuvant chemotherapy (NAC) in cN1

150 ate (FNR) of 12.6% with sentinel lymph node (SLN) surgery after neoadjuvant chemotherapy in women pre

151 ccuracy of the isotopic sentinel lymph node (SLN) technique correlated with hyperextensive pelvic res

152 with metastases in the sentinel lymph node (SLN).

153 signal emanating from sentinel lymph nodes (SLNs) approximately 2 d after injection and imaging of a

154 r with 1 or 2 positive sentinel lymph nodes (SLNs) are recommended to undergo axillary lymph node dis

155 essment of nonenlarged sentinel lymph nodes (SLNs) for diagnosing metastases in early-stage cervical

156 rs and 1 to 2 involved sentinel lymph nodes (SLNs) having breast-conserving therapy had no difference

157 ning nodes) as well as sentinel lymph nodes (SLNs) may provide more accurate assessment of the pathol

158 patients with positive sentinel lymph nodes (SLNs) randomized either to axillary lymph node dissectio

159 th one to two positive sentinel lymph nodes (SLNs) who undergo lumpectomy, radiotherapy (RT), and sys

160 the number of resected sentinel lymph nodes (SLNs), our primary end point was the mean number of hist

161 , or SLN size, compared with the nearest non-SLN, showed no association with metastases (P= 0.055-0.7

162 araaortic lymph nodes, which represented non-SLNs, we assayed all lymph nodes for radioactivity and f

163 predicted metastatic invasion of nonenlarged SLNs, with quality-adjusted odds ratios of 1.42 (95% con

164 ion of one allele of the SLN gene normalizes SLN expression, restores SERCA function, mitigates skele

165 A-SLN complex correlated with the ability of SLN to decrease the maximal activity of SERCA, which is

166 y of PLN to increase the maximal activity of SLN.

167 membranes indicating that the S-acylation of SLN or of other proteins is required for this effect on

168 Interestingly, adaptation of SLN(-/-) mice to mild cold conditions (16 degrees C) sig

169 gery would be acceptable for the adoption of SLN surgery for women with node-positive breast cancer t

170 R) or data on expected and observed cases of SLN positivity and histologic regression were included.

171 n this study we demonstrate that deletion of SLN N-terminal residues (2)ERSTQ leads to loss of the un

172 d node during SLN surgery reduces the FNR of SLN surgery after neoadjuvant chemotherapy.

173 rtant to ensure successful identification of SLN(s) after NAC.

174 re was significantly increased likelihood of SLN identification with injection dose >=1 mg compared t

175 re was significantly increased likelihood of SLN identification with radiologically solid nodules com

176 sed to develop a model for the likelihood of SLN metastasis from molecular, clinical, and histologic

177 SLN expression in UCP1-KO mice, and loss of SLN is compensated by increased expression of UCP1 and b

178 Debate remains as to the optimal method of SLN detection.

179 meta-analyses were used to summarize ORs of SLN positivity and histologic regression.

180 rative AUS results are considered as part of SLN surgery.

181 To determine the structural regions of SLN that mediate uncoupling of SERCA, we employed mutage

182 is study show that there is up-regulation of SLN expression in UCP1-KO mice, and loss of SLN is compe

183 lts of this analysis showed that the risk of SLN positivity was significantly lower in patients with

184 rthermore, molecular dynamics simulations of SLN and SERCA interaction showed a rearrangement of SERC

185 our studies highlight that the N termini of SLN and PLB influence their respective unique functions.

186 nd an updated randomized controlled trial of SLN biopsy, as well as two randomized controlled trials

187 udy contributes to a better understanding of SLN as a function of the bioactive lipid.

188 sition and beta-carotene bioaccessibility of SLNs with different solid lipids, being blends of medium

189 ng and real-time intraoperative detection of SLNs during robotic surgery.

190 tigraphy or intraoperative identification of SLNs.

191 The number of SLNs identified using the near infrared fluorescence tec

192 Presence of ENE on SLN dissection is associated with N2 disease.

193 , and 38 (18.3%) had ENE larger than 2 mm on SLN dissection.

194 ncement, cortical thickness, round shape, or SLN size, compared with the nearest non-SLN, showed no a

195 we sought to understand how loss of UCP1 or SLN is compensated during cold exposure and whether they

196 This corresponded to a pooled overall SLN detection OR of 2.5 (95% CI, 1.2-5.3) in favor of SP

197 ng with SPECT/CT results in superior overall SLN detection in comparison with planar lymphoscintigrap

198 Pig SLN is also fully palmitoylated/oleoylated on its Cys-9

199 inal tail, zfPLN appears to use a hybrid PLN-SLN inhibitory mechanism.

200 In the case of a positive SLN biopsy, CLND or careful observation are options for

201 A positive SLN was identified in 12.3% of all patients.

202 zed controlled trials of CLND after positive SLN biopsy, were included.

203 uvant HDI in patients with a single positive SLN was found.

204 of the NSLN status in patients with positive SLN.

205 nodal burden, patients with 1 or 2 positive SLNs and ENE 2 mm or smaller demonstrated recurrence and

206 T1 or T2 breast cancer with 1 or 2 positive SLNs.

207 All cSCCs with positive SLNs were greater than 2 cm in diameter.

208 spectively, using a 10% cutoff for predicted SLN metastasis risk).

209 ic PET/CT scan was acquired for preoperative SLN mapping.

210 rogen receptor had an impact on preoperative SLN visualization and intraoperative localization.

211 In cervical cancer patients, preoperative SLN imaging with SPECT/CT results in superior overall SL

212 using a central composite design, producing SLNs with sizes of <100nm.

213 We find that native rabbit SLN is modified by a fatty acid anchor on Cys-9 with a p

214 The radioisotope SLN identification method up to the common iliac region

215 ectly and in complex with SERCA1 and reduces SLN's inhibitory effect on SERCA1 activity.

216 The AAV treatment markedly reduces SLN expression, attenuates muscle pathology and improves

217 Here we show that reducing SLN levels ameliorates dystrophic pathology in the sever

218 ew of the literature was conducted regarding SLN biopsy and completion lymph node dissection (CLND) a

219 tion, S-acylation/deacylation also regulates SLN activity.

220 The time between injection and robotic SLN mapping ranged from 32 to 38 h.

221 Approximately 36 h later, robotic SLN mapping was performed using a fluorescence-capable c

222 Recommendations Routine SLN biopsy is not recommended for patients with thin mel

223 Sarcolipin (SLN) is a novel regulator of sarcoplasmic reticulum Ca(2

224 Sarcolipin (SLN) is a regulatory peptide present in sarcoplasmic ret

225 Sarcolipin (SLN) is an inhibitor of the sarco/endoplasmic reticulum

226 PLB), an affinity modulator, and sarcolipin (SLN), an uncoupler.

227 ity with phospholamban (PLN) and sarcolipin (SLN), which inhibit SERCA, the membrane pump that contro

228 proteins phospholamban (PLN) and sarcolipin (SLN).

229 ctivity, phospholamban (PLB) and sarcolipin (SLN).

230 wn being phospholamban (PLN) and sarcolipin (SLN).

231 based) and skeletal muscle (i.e. sarcolipin (SLN)-based) thermogenesis processes play important roles

232 n in a manner similar to that of sarcolipin (SLN).

233 We recently showed that sarcolipin (SLN), an uncoupler of the sarco(endo)plasmic reticulum C

234 PLB gets dislodged from Ca(2+)-bound SERCA, SLN continues to bind SERCA throughout its kinetic cycle

235 A projection map of the SERCA-SLN complex was determined to a resolution of 8.5 angstr

236 This SERCA-SLN complex correlated with the ability of SLN to decrea

237 Significantly, SLN promoted the interaction between sAnk1 and SERCA1 wh

238 kout (Sln(-/-)) and skeletal muscle-specific SLN overexpression (Sln(OE)) mice to explore energy meta

239 d in the node, the clip location at surgery (SLN or ALND) was evaluated.

240 Unilateral surgical SLN detection did not validate bilateral pelvic lymph no

241 These results further confirm that SLN-based thermogenesis is a key player in muscle non-sh

242 On the basis of these data we propose that SLN is a novel target for enhancing whole-body energy ex

243 We recently showed that SLN plays an important role in cold- and diet-induced th

244 Earlier studies have shown that SLN and phospholamban, the other well studied small SERC

245 Taken together, our findings suggest that SLN reduction is a promising therapeutic approach for DM

246 The SLN FNR was not different based on AUS results; however,

247 The SLN identification rate after NAC was higher when mappin

248 The SLN identification rate was 78.6% with blue dye alone; 9

249 The SLN pentamer was found to interact with transmembrane se

250 The SLN was made of unique PEGylated lipids and combination

251 The SLN-loaded 5-FU was developed by utilizing a Strategic a

252 ients (DR: 86.9%, 95% CI: 81.8 to 91.0), the SLN and TLN were identical in 129 patient (64.8%).

253 y treatment did not significantly affect the SLN identification rate.

254 ere used to model the parameters against the SLN status.

255 dynamics simulations provided models for the SLN pentamer and the novel interaction between SERCA and

256 Although this domain is distinct from the SLN luminal tail, zfPLN appears to use a hybrid PLN-SLN

257 ng the likelihood of failure to identify the SLN relative to using radiolabeled colloid +/- blue dye

258 id and/or methylene blue dye to identify the SLN, which is most likely to contain metastatic cancer c

259 ing, followed by immunohistochemistry if the SLN was free of metastasis.

260 pathology but with melanoma detected in the SLN by RT-PCR, there was no OS benefit for CLND or CLND+

261 ts had lymph node metastases, 19 only in the SLN.

262 Intraoperative visualization of the SLN by indocyanine green before skin incision was succes

263 Germline inactivation of one allele of the SLN gene normalizes SLN expression, restores SERCA funct

264 to radioisotope in the identification of the SLN in the presence of a positive preoperative lymphosci

265 moves the fatty acids from a majority of the SLN pool.

266 ansport through the lymphatic vessels to the SLN is then visualized with dynamic PET/CT.

267 transfer of the PLB cytosolic domain to the SLN transmembrane (TM) and luminal tail causes the chime

268 t of SERCA residues that is altered when the SLN N terminus is deleted.

269 tients where the clipped node was within the SLN specimen, the FNR was 6.8% (confidence interval [CI]

270 The SLNs were prepared from Geleol(R) and Tween(R)80 as a li

271 The SLNs were then incorporated into a polymeric hydrogel wh

272 s identify only the anatomic location of the SLNs and do not provide information on their tumor statu

273 All of the SLNs defined by the ex vivo gamma-well assay of (99m)Tc

274 tion, indicating the high possibility of the SLNs to be taken by the lymphatic system.

275 he clip-containing lymph node was one of the SLNs.

276 ymph nodes, selective evaluation of only the SLNs-for size and absence of sharp demarcation-can be us

277 ion, popliteal lymph nodes, representing the SLNs, were dissected with the assistance of the FireFly

278 injected dose; the amount of dye within the SLNs ranged from 8.5 to 88 pmol, which was equivalent to

279 emoval of the clip-containing lymph nodes to SLN dissection may identify patients for limited nodal s

280 educe the FNR in Z1071 patients with >/= two SLNs removed from 12.6% to 9.8% when preoperative AUS re

281 ere, we functionally characterized wild-type SLN and a pair of mutants, Asn(4)-Ala and Thr(5)-Ala, wh

282 ystals of SERCA in the presence of wild-type SLN by electron cryomicroscopy.

283 Toward this goal, we generated a UCP1;SLN double knock-out (DKO) mouse model and challenged th

284 where only patients with normal AUS undergo SLN surgery would potentially reduce the FNR in Z1071 pa

285 a >/= 1.0 mm Breslow thickness and underwent SLN biopsy.

286 nical T0-T4,N1-N2,M0 breast cancer underwent SLN surgery and axillary dissection (ALND) after neoadju

287 Five patients underwent SLN dissection in addition to removal of the clip-contai

288 icant difference in the number of visualized SLNs was observed at a pooled ratio of 1.2 (95% CI, 0.9-

289 Outcome of interest was SLN biopsy metastasis within 90 days of melanoma diagnos

290 nt roles, the structural mechanisms by which SLN modulates SERCA-dependent contractility and thermoge

291 AT, and TP53 expression were associated with SLN metastasis.

292 r new molecular risk factors associated with SLN positivity in thin and intermediate-thickness melano

293 As sAnk1 is coexpressed with SLN in muscle, we sought to determine whether these two

294 1 cm surgical excision margin) combined with SLN biopsy (followed by an immediate completion lymph no

295 r determining residual disease compared with SLN identification alone.

296 se results suggest that sAnk1 interacts with SLN both directly and in complex with SERCA1 and reduces

297 y examined overall survival of patients with SLN metastases undergoing breast-conserving therapy rand

298 improves the identification of patients with SLN metastases within 90 days of melanoma diagnosis.

299 pport not recommending CLND in patients with SLN metastasis.

300 Women with SLN metastases who will undergo mastectomy should be off